30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

Vericel Reports 1Q19 MACI Revenue of $16.6MM, +37% vs. 1Q18 -


Vericel reports 1Q19 MACI revenue of USD $16.6MM, +37% vs. 1Q18.

  • Biopsy and implant trends indicate that MACI is on track to potentially exceed previous guidance
  • The company provided revised guidance for MACI and Epicel combined, raising it to $100MM to $114MM, up from $108MM to $112MM; MACI is expected to account for at least $90MM of the updated guidance
  • Expanded MACI salesforce now deployed into the field, bringing total number of sales territories to 48


MACI sales and growth on an as-reported basis ($MM):

  1Q19 1Q18 $ Chg % Chg
Orthobiologics $16.6 $12.1 $4.5 37.0%

Net earnings ($MM):

1Q19 Amount ($MM) % of Sales
Sales $21.8  
   Cost of Sales -$8.6 39.6%
   Other $0.5 2.3%
   R & D -$3.0 13.8%
   Selling and Admin -$13.5 62.0%
Net Earnings -$2.8 -13.0%


Sources: Vericel; ORTHOWORLD estimates

Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.